<?xml version="1.0" encoding="UTF-8"?>
<clinical_study>
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 09, 2025</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT00078754</url>
  </required_header>
  <id_info>
    <org_study_id>R01MH066984</org_study_id>
    <secondary_id>R01MH066984</secondary_id>
    <secondary_id>DATR A5-ETMA</secondary_id>
    <nct_id>NCT00078754</nct_id>
  </id_info>
  <brief_title>A Comparison of Fluoxetine and Divalproex for the Treatment of Intermittent Explosive Disorder</brief_title>
  <official_title>Fluoxetine and Divalproex: Treatment Correlates in IED</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>This study will compare the medications fluoxetine (Prozac®) and divalproex (Depakote®)&#xd;
for the treatment of aggressive behavior in individuals with Intermittent Explosive&#xd;
Disorder (IED).</textblock>
  </brief_summary>
  <detailed_description>
    <textblock>IED is a condition characterized by a failure to resist aggressive impulses. IED is a&#xd;
behavioral defined condition for which effective treatments have not been identified.&#xd;
Research suggests that serotonin (5-HT), a chemical that helps regulate mood and&#xd;
emotions, may play a role in the response to pharmacological IED treatments. This study&#xd;
will examine the relationship between 5-HT receptors and response to treatment with&#xd;
fluoxetine or divalproex. In addition, this study will examine people with IED and those&#xd;
without the condition to determine whether there are differences in their 5-HT receptor&#xd;
and transporter systems.&#xd;
&#xd;
Participants in this study will be randomly assigned to receive either fluoxetine,&#xd;
divalproex, or placebo for 12 weeks. Scale ratings will be used to assess the aggression&#xd;
levels of participants. Biologic evaluations of the 5-HT system will be conducted&#xd;
throughout the study.</textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overt Aggression Scale-Modified for Outpatient Use (OAS-M)</measure>
    <time_frame>Measured at Week 12</time_frame>
    <description>OAS-M is a validated instrument that measures aggression. Anti-aggressive effect of the&#xd;
drug/placebo was measured by the aggression score from OAS-M. Possible scores for&#xd;
aggression range from 0 (no aggression) to infinity (because the score is calculated by&#xd;
the number of times an aggressive behavior occurred, which theoretically has no possible&#xd;
maximum). Therefore the bigger number, the worse anti-aggression effect, thus the worse&#xd;
outcome. In each weekly visit, OAS-M score was calculated for the past week.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OAS-M</measure>
    <time_frame>Measured at Week 12</time_frame>
    <description>Overt Aggression Scale Modified for Outpatient Use. Minimum value = 0 Maximum value =&#xd;
Infinity. Higher scores means worse outcome.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Intermittent Explosive Disorder</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will to receive treatment with fluoxetine for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will to receive treatment with divalproex for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will to receive treatment with placebo for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoxetine</intervention_name>
    <description>Fluoxetine capsules by mouth, up to 60 mg daily</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Divalproex</intervention_name>
    <description>Divalproex ER capsules by mouth, up to 3000 mg daily</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules by mouth, up to 8 capsules daily</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>Inclusion Criteria:&#xd;
&#xd;
  -  Diagnosis of Intermittent Explosive Disorder (IED)&#xd;
&#xd;
  -  In good physical health&#xd;
&#xd;
  -  Overt Aggression Scale-Modified (OAS-M) score of 15 or higher at screening&#xd;
&#xd;
  -  Willing and able to comply with the study requirements&#xd;
&#xd;
Exclusion Criteria:&#xd;
&#xd;
  -  Life history of bipolar disorder, schizophrenia, organic mental syndrome, or mental&#xd;
     retardation&#xd;
&#xd;
  -  Current major depressive disorder, with a Hamilton Depression (HAM-D) Scale score&#xd;
     higher than 18&#xd;
&#xd;
  -  Current alcohol or drug abuse or dependence&#xd;
&#xd;
  -  Active medical conditions that will interfere with the study&#xd;
&#xd;
  -  Thymoleptic or neuroleptic treatments&#xd;
&#xd;
  -  Presence of the following serious and active medical conditions: demyelinating or&#xd;
     progressive degenerative disorders; central nervous system infection; progressive&#xd;
     degenerative neurological disorder; ischemic heart disease; respiratory, renal, or&#xd;
     liver disease; Type I diabetes; malignant neoplasm; hyper- or hypo-coagulopathy;&#xd;
     Acquired Immune Deficiency Syndrome (AIDS); or seizure disorder. Participants with a&#xd;
     history of more than two febrile seizures prior to 1 year of age are eligible.&#xd;
&#xd;
  -  Chronic, ongoing treatment with the following classes of medications:&#xd;
     antidepressants, neuroleptics, mood stabilizers, antianxiety agents, hypnotics,&#xd;
     narcotics or synthetic narcotics, barbiturates, stimulants, anti-migraine agents,&#xd;
     anti-epileptics, non-beta-blocking or Ca-channel blocking anti-arrhythmic agents&#xd;
     prescribed to treat cardiac arrhythmia, anticoagulants, immunomodulators,&#xd;
     anti-neoplastic agents, or HIV antiviral agents&#xd;
&#xd;
  -  Ongoing psychotherapeutic treatment for the treatment of IED or anger that was&#xd;
     started less than 3 months before study entry&#xd;
&#xd;
  -  Hypersensitivity to fluoxetine or divalproex&#xd;
&#xd;
  -  Pregnancy</textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emil F. Coccaro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 5, 2004</study_first_submitted>
  <study_first_submitted_qc>March 5, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2004</study_first_posted>
  <results_first_submitted>February 19, 2014</results_first_submitted>
  <results_first_submitted_qc>December 29, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 31, 2014</results_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <mesh_term>Disruptive, Impulse Control, and Conduct Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <mesh_term>Valproic Acid</mesh_term>
    <mesh_term>Fluoxetine</mesh_term>
  </intervention_browse>
  <clinical_results>
    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group A - Fluoxetine Drug</title>
          <description>Participants will to receive treatment with fluoxetine for 12 weeks&#xd;
&#xd;
Fluoxetine: Fluoxetine capsules by mouth, up to 60 mg daily</description>
        </group>
        <group group_id="P2">
          <title>Group B - Divalproex Drug</title>
          <description>Participants will to receive treatment with divalproex for 12 weeks&#xd;
&#xd;
Divalproex: Divalproex ER capsules by mouth, up to 3000 mg daily</description>
        </group>
        <group group_id="P3">
          <title>Group C - Placebo</title>
          <description>Participants will to receive treatment with placebo for 12 weeks&#xd;
&#xd;
Placebo: Placebo capsules by mouth, up to 8 capsules daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>
    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group A - Fluoxetine Drug</title>
          <description>Participants will to receive treatment with fluoxetine for 12 weeks&#xd;
&#xd;
Fluoxetine: Fluoxetine capsules by mouth, up to 60 mg daily</description>
        </group>
        <group group_id="B2">
          <title>Group B - Divalproex Drug</title>
          <description>Participants will to receive treatment with divalproex for 12 weeks&#xd;
&#xd;
Divalproex: Divalproex ER capsules by mouth, up to 3000 mg daily</description>
        </group>
        <group group_id="B3">
          <title>Group C - Placebo</title>
          <description>Participants will to receive treatment with placebo for 12 weeks&#xd;
&#xd;
Placebo: Placebo capsules by mouth, up to 8 capsules daily</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="31"/>
            <count group_id="B4" value="90"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="90"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>overt aggression scale-modified (OAS-M).</title>
          <description>OAS-M is a validated instrument that measures aggression. Possible scores for aggression&#xd;
range from 0 (no aggression) to infinity (because the score is calculated by the number&#xd;
of times an aggressive behavior occurred, which theoretically has no possible maximum).&#xd;
Therefore the bigger number, the more aggression. OAS-M score was calculated for the past&#xd;
week before the visit.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.75" spread="46.88"/>
                    <measurement group_id="B2" value="36.96" spread="26.42"/>
                    <measurement group_id="B3" value="66.08" spread="77.99"/>
                    <measurement group_id="B4" value="47.30" spread="56.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>
    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overt Aggression Scale-Modified for Outpatient Use (OAS-M)</title>
        <description>OAS-M is a validated instrument that measures aggression. Anti-aggressive effect of the&#xd;
drug/placebo was measured by the aggression score from OAS-M. Possible scores for&#xd;
aggression range from 0 (no aggression) to infinity (because the score is calculated by&#xd;
the number of times an aggressive behavior occurred, which theoretically has no possible&#xd;
maximum). Therefore the bigger number, the worse anti-aggression effect, thus the worse&#xd;
outcome. In each weekly visit, OAS-M score was calculated for the past week.</description>
        <time_frame>Measured at Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A - Fluoxetine Drug</title>
            <description>Participants will to receive treatment with fluoxetine for 12 weeks&#xd;
&#xd;
Fluoxetine: Fluoxetine capsules by mouth, up to 60 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Group B - Divalproex Drug</title>
            <description>Participants will to receive treatment with divalproex for 12 weeks&#xd;
&#xd;
Divalproex: Divalproex ER capsules by mouth, up to 3000 mg daily</description>
          </group>
          <group group_id="O3">
            <title>Group C - Placebo</title>
            <description>Participants will to receive treatment with placebo for 12 weeks&#xd;
&#xd;
Placebo: Placebo capsules by mouth, up to 8 capsules daily</description>
          </group>
        </group_list>
        <measure>
          <title>Overt Aggression Scale-Modified for Outpatient Use (OAS-M)</title>
          <description>OAS-M is a validated instrument that measures aggression. Anti-aggressive effect of the&#xd;
drug/placebo was measured by the aggression score from OAS-M. Possible scores for&#xd;
aggression range from 0 (no aggression) to infinity (because the score is calculated by&#xd;
the number of times an aggressive behavior occurred, which theoretically has no possible&#xd;
maximum). Therefore the bigger number, the worse anti-aggression effect, thus the worse&#xd;
outcome. In each weekly visit, OAS-M score was calculated for the past week.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.86" spread="4.11"/>
                    <measurement group_id="O2" value="15.73" spread="10.15"/>
                    <measurement group_id="O3" value="8.88" spread="3.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <method>ANCOVA</method>
            <p_value>0.622</p_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OAS-M</title>
        <description>Overt Aggression Scale Modified for Outpatient Use. Minimum value = 0 Maximum value =&#xd;
Infinity. Higher scores means worse outcome.</description>
        <time_frame>Measured at Week 12</time_frame>
        <population>OAS-M Scores in Placebo, Fluoxetine, Divalproex Arms as a function of LHA Score.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluoxetine</title>
            <description>20-60 mg po qd for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Divalproex</title>
            <description>Up to 3000 mg po qd for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Up to 8 capsules po qd for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>OAS-M</title>
          <description>Overt Aggression Scale Modified for Outpatient Use. Minimum value = 0 Maximum value =&#xd;
Infinity. Higher scores means worse outcome.</description>
          <population>OAS-M Scores in Placebo, Fluoxetine, Divalproex Arms as a function of LHA Score.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>High Aggression Group</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2" spread="5.0"/>
                    <measurement group_id="O2" value="13.7" spread="4.8"/>
                    <measurement group_id="O3" value="19.5" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium Aggression Group</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.1" spread="7.6"/>
                    <measurement group_id="O2" value="29.6" spread="8.0"/>
                    <measurement group_id="O3" value="26.9" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The hypothesis was that subjects with LHA Scores = 18 or more would respond better to&#xd;
divalproex (than fluoxetine) while those with LHA scores = or &lt; 17 would respond better&#xd;
to fluoxetine (than divalproex).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <method>ANCOVA</method>
            <method_desc>The LHA Score F[1,83] = 4.91, p = 0.029; Condition F[2,83] = 0.20, p = 0.815; Condition x&#xd;
LHA Score F[2,83] = 0.255, p = 0.799.</method_desc>
            <p_value>0.029</p_value>
            <p_value_desc>LHA score main effect.</p_value_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ANCOVA at endpoint with baseline OAS-M AGG score as covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <method>ANCOVA</method>
            <method_desc>Baseline OAS-M Aggression score as covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>19.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.7</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <p_value>0.80</p_value>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>
    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group A - Fluoxetine Drug</title>
          <description>Participants will to receive treatment with fluoxetine for 12 weeks&#xd;
&#xd;
Fluoxetine: Fluoxetine capsules by mouth, up to 60 mg daily</description>
        </group>
        <group group_id="E2">
          <title>Group B - Divalproex Drug</title>
          <description>Participants will to receive treatment with divalproex for 12 weeks&#xd;
&#xd;
Divalproex: Divalproex ER capsules by mouth, up to 3000 mg daily</description>
        </group>
        <group group_id="E3">
          <title>Group C - Placebo</title>
          <description>Participants will to receive treatment with placebo for 12 weeks&#xd;
&#xd;
Placebo: Placebo capsules by mouth, up to 8 capsules daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>hyponatremia/hypokalemia</sub_title>
                <description>lab results showed hyponatremia/hypokalemia.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Headaches</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Trembling</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Faintness or dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Numbness or tingling in parts of your body</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Feeling tense or keyed up</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Nervousness or shakiness inside</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Soreness in your muscle, back, joints</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Spells of terror or panic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hot or cold spells</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Heart pounding or racing</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pains in the heart or chest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Trouble getting your breath</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Trouble remembering things</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Feeling that familiar things are strange or unreal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Nausea or upset stomach</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Increased salivation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Difficulty urinating</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>
    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Most participants did not have stable OAS-M Aggression scores from screening to&#xd;
randomization. Note that this was not a requirement for this study; only that&#xd;
OAS-Aggression scores were 15 or higher at screening.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Emil F. Coccaro, MD</name_or_title>
      <organization>The University of Chicago</organization>
      <phone>773-834-4083</phone>
      <email>ecoccaro@yoda.bsd.uchicago.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
